Get to know our clinical trials

Trial of mesenchymal stromal cells compared to best available therapy in pediatric participants with steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation

EL OBJETIVO PRINCIPAL DE ESTE ESTUDIO ES CONOCER LA EFICACIA Y LA SEGURIDAD DEL MC0518 EN COMPARACIÓN CON LOS MEJORES TRATAMIENTOS DISPONIBLES (MTD) ACTUALES EN PACIENTES PEDIÁTRICOS.

Imagen del Dr. Jose Rifón Roca, especialista de Hematología de la Clínica Universidad de Navarra. El Dr. Rifón se dedica preferencialmente a la oncohematología.
Dr. José Rifón Curriculum
Specialist Hematology and Hemotherapy Department
Navarre headquarters
Madrid headquarters
Cancer Center
Hematologic Cancer Area
Status
In recruitment
headquarters
Pamplona
Early phase

Technical Summary

  • PHASE II, RANDOMIZED, UNBLINDED, CONTROLLED, MULTICENTER, UNBLINDED TRIAL OF FIRST-LINE MC0518 STROMAL SCHMAL CELL THERAPY COMPARED TO BEST AVAILABLE THERAPY IN PEDIATRIC PARTICIPANTS WITH ACUTE STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (BALDER TRIAL).
  • Code EudraCT: 2023-503952-28-00
  • Protocol number: MC-MSC.2/aGvHD
  • Promoter: Medac GmbH

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION